Section one: Contracting authority
one.1) Name and addresses
NHS England
1st Floor, Quarry House, Quarry Hill
Leeds
LS2 7UE
Contact
NHSE Commercial Team
england.commercialqueries@nhs.net
Country
United Kingdom
Region code
UKE - Yorkshire and the Humber
Internet address(es)
Main address
Buyer's address
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
https://health-family.force.com/s/Welcome
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
https://health-family.force.com/s/Welcome
Tenders or requests to participate must be submitted to the above-mentioned address
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at
https://health-family.force.com/s/Welcome
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Cancer Vaccines Launch Pad (CVLPP
two.1.2) Main CPV code
- 85100000 - Health services
two.1.3) Type of contract
Services
two.1.4) Short description
The CVLP is a strategic priority and collaboration between NHS England, the Department of Health and Social Care (DHSC), the Office for Life Sciences (OLS), the National Institute of Health Research (NIHR) and Genomics England (GEL), with the aim to facilitate access to personalised cancer vaccine research trials. The project was jointly announced in July 2023 with the Secretary of State and in partnership with the Prime Minister. See link (https://www.gov.uk/government/news/major-agreement-to-deliver-new-cancer-vaccine-trials#:~:text=It%20will%20work%20by%20creating,become%20part%20of%20standard%20care)
Through the CVLP platform, cancer patients from across a network of up to 140 NHS cancer care providers will be asked to consent to be put forward for clinical trials. Their surplus tissue samples, obtained through standard of care pathways, will be used to assess their eligibility. The detail of any available trials will be shared with the participant and their treating clinical team to see if the patient wishes to take part, and if so, the patient will travel to the nearest trial site to access the clinical trial.
The CVLP is company agnostic and is being set up in a phased approach with a small number of Trusts to test the pathway from September 2023. For the first phase, the CVLP is supporting one cancer vaccine clinical trial. It is likely that three to four additional trials will be brought into the CVLP during 2024.
NHS England is looking for a supplier to provide the digital infrastructure and clinical liaison function to manage the end-to-end pathway of the CVLP for up to 2000 patients until March 2025.
Initial term is 15 months to a maximum value of £1,400,000. There is provision for a potential 12 month extension up to a maximum value £700k but this is subject to approvals by NHSE.
To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome.
Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at:
Phone: 0800 9956035
E-mail: support-health@atamis.co.uk
two.1.5) Estimated total value
Value excluding VAT: £2,100,000
two.1.6) Information about lots
This contract is divided into lots: No
two.2) Description
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
As per short description
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £2,100,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
3 January 2024
End date
31 March 2025
This contract is subject to renewal
Yes
Description of renewals
Up to a single 12 month extension from 01/04/2025. Any extension period is subject to approval of NHS England.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: No
four.2) Administrative information
four.2.2) Time limit for receipt of tenders or requests to participate
Date
24 November 2023
four.2.4) Languages in which tenders or requests to participate may be submitted
English
four.2.6) Minimum time frame during which the tenderer must maintain the tender
Duration in months: 3 (from the date stated for receipt of tender)
four.2.7) Conditions for opening of tenders
Date
24 November 2023
Local time
12:00pm
Section six. Complementary information
six.1) Information about recurrence
This is a recurrent procurement: No
six.4) Procedures for review
six.4.1) Review body
High Court and Court of Appeal of England and Wales
Strand
London
WC2A 2LL
InternationalRelationsJudicialOffice@judiciary.uk
Country
United Kingdom